600535 Stock Overview
Engages in the pharmaceutical business in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Tasly Pharmaceutical Group Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥14.47 |
| 52 Week High | CN¥18.00 |
| 52 Week Low | CN¥12.24 |
| Beta | 0.44 |
| 11 Month Change | -5.05% |
| 3 Month Change | 5.16% |
| 1 Year Change | -5.30% |
| 33 Year Change | 9.13% |
| 5 Year Change | -5.18% |
| Change since IPO | -51.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600535 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.4% | -1.5% | -2.1% |
| 1Y | -5.3% | -9.4% | 2.8% |
Return vs Industry: 600535 exceeded the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 600535 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 600535 volatility | |
|---|---|
| 600535 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 600535 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600535's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 9,223 | Jing Su | www.taslypharma.com |
Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. It provides cardiovascular, anti-tumor, cold and fever, liver disease treatment, and other disease solutions. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is based in Tianjin, China.
Tasly Pharmaceutical Group Co., Ltd Fundamentals Summary
| 600535 fundamental statistics | |
|---|---|
| Market cap | CN¥21.62b |
| Earnings (TTM) | CN¥881.05m |
| Revenue (TTM) | CN¥8.57b |
24.5x
P/E Ratio2.5x
P/S RatioIs 600535 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600535 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.57b |
| Cost of Revenue | CN¥2.85b |
| Gross Profit | CN¥5.71b |
| Other Expenses | CN¥4.83b |
| Earnings | CN¥881.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 27, 2024
| Earnings per share (EPS) | 0.59 |
| Gross Margin | 66.70% |
| Net Profit Margin | 10.29% |
| Debt/Equity Ratio | 16.2% |
How did 600535 perform over the long term?
See historical performance and comparison